A Phase 3 interventional study of Sitagliptin/Simvastatin FDC and Sitagliptin in Type 2 Diabetes Mellitus, sponsored by Merck Sharp & Dohme LLC. Terminated. Open to participants aged 18 Years to 79 Years. Per ClinicalTrials.gov, last updated 2018-08-24.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, none of them phase 3. sitagliptin · Diabetes Mellitus, Type 2.
Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, this one is the 57th largest by enrollment of the 197 interventional ones that give a count, is one of 16 that started in 2012, is one of 74 in phase 3, and was the 122nd registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:
Beijing Chao Yang Hospital · Sites in China
Ages 18–65
Bahria University · Sites in Pakistan
Ages 30–55
Yonsei University · Sites in Korea, Republic of
Ages 19–75
By country, each count listing its studies:
sitagliptin: first FDA approval 2006 (JANUVIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years to 79 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
198 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 11 · Phase 3 74 · Phase 4 68
First in 2003; this study’s year is marked. 16 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 299 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 102 across the 197 interventional studies. Of the 172 that completed or were terminated, 117 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
103 of 198 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc: none open now, none under way, none of them phase 3. Of 181 finished, 150 (83%) have results posted.
Among the 181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc, this one is the 73rd largest by enrollment of the 170 interventional ones that give a count, is one of 20 that started in 2012, is one of 86 in phase 3, and was the 134th registered.
Merck & Co., Inc’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 181 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the efficacy and safety of sitagliptin/simvastatin fixed-dose combination (FDC) in participants with T2DM who have inadequate glycemic control while on metformin monotherapy. The primary hypothesis of this study is that after 16 weeks of therapy, the mean change from baseline in hemoglobin A1C (A1C) in participants treated with sitagliptin/simvastatin FDC is non-inferior compared to sitagliptin alone.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Sitagliptin 100 mg/simvastatin 40 mg FDC plus placebo to sitagliptin plus placebo to simvastatin administered orally once daily in the evening for 16 weeks. Participants will continue on their stable pre-screening metformin dose and dosing regimen of \>=1500 mg daily for the duration of the study. Participants may receive glimepiride 1 mg once daily or 2 mg once daily (may be up-titrated to 6 mg once daily) as rescue therapy.
Drug: Sitagliptin/Simvastatin FDC · Drug: Placebo to sitagliptin · Drug: Placebo to simvastatin · Drug: Metformin · Drug: Glimepiride
Sitagliptin 100 mg plus placebo to simvastatin plus placebo to sitagliptin/simvastatin FDC administered orally once daily in the evening for 16 weeks. Participants will continue on their stable pre-screening metformin dose and dosing regimen of \>=1500 mg daily for the duration of the study. Participants may receive glimepiride 1 mg once daily or 2 mg once daily (may be up-titrated to 6 mg once daily) as rescue therapy.
Drug: Sitagliptin · Drug: Placebo to simvastatin · Drug: Placebo to Sitagliptin/Simvastatin FDC · Drug: Metformin · Drug: Glimepiride
Simvastatin 40 mg plus placebo to sitagliptin plus placebo to sitagliptin/simvastatin FDC administered orally once daily in the evening for 16 weeks. Participants will continue on their stable pre-screening metformin dose and dosing regimen of \>=1500 mg daily for the duration of the study. Participants may receive glimepiride 1 mg once daily or 2 mg once daily (may be up-titrated to 6 mg once daily) as rescue therapy.
Drug: Simvastatin · Drug: Placebo to sitagliptin · Drug: Placebo to Sitagliptin/Simvastatin FDC · Drug: Metformin · Drug: Glimepiride
Drug pages: Sitagliptin · Simvastatin
Sitagliptin 100 mg/Simvastatin 40 mg fixed-dose combination tablet
Also known as: MK-0431D, Juvisync™, Juvicor®
Sitagliptin 100 mg tablet
Also known as: MK-0431, Januvia®, Tesavel®, Xelevia®, Ristaben®
Simvastatin 40 mg tablet
Also known as: MK-0733, Zocor®
Matching placebo to sitagliptin 100 mg tablet
Matching placebo to simvastatin 40 mg tablet
Matching placebo to sitagliptin 100 mg/simvastatin 40 mg FDC tablet
Participants will continue on their stable, pre-screening metformin daily dose of \>= 1500 mg for at least 12 weeks prior to randomization and during the study
Also known as: Fortamet®, Glucophage®, Glucophage® XR, Glumetza®, Riomet®, Metgluco®, Glycoran®
Following randomization, participants requiring glycemic rescue may receive open-label glimepiride initiated at a dose of 1 mg/day or 2 mg/day which may be up-titrated to 6 mg/day taken once daily with breakfast or the first main meal of the day.
Also known as: Amaryl®, Glimy
Change From Baseline in Hemoglobin A1C (A1C) at Week 16 (Sitagliptin/Simvastatin FDC vs. Sitagliptin)
A1C is measured as percent. Thus, this change from baseline reflects the Week 16 A1C percent minus the Week 0 A1C percent. This primary outcome measure only includes results for sitagliptin/simvastatin FDC vs. sitagliptin. Results for simvastatin are presented below under secondary outcome measures.
Time frame: Baseline and Week 16
Number of Participants Who Experienced at Least One Adverse Event (AE)
Excludes data after rescue therapy. Adverse event is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the Sponsor's product, whether or not considered related to the use of the product.
Time frame: Up to 16 weeks for non-serious AEs, up to 18 weeks for serious AEs
Number of Participants Who Discontinued Study Drug Due to an Adverse Event
Excludes data after rescue therapy. Adverse event is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the Sponsor's product, whether or not considered related to the use of the product.
Time frame: Up to 16 weeks
Change From Baseline in A1C at Week 16 (Sitagliptin/Simvastatin FDC vs. Simvastatin)
A1C is measured as percent. Thus, this change from baseline reflects the Week 16 A1C percent minus the Week 0 A1C percent. This primary outcome measure only includes results for sitagliptin/simvastatin FDC vs. simvastatin. Results for sitagliptin are presented above under primary outcome measures.
Time frame: Baseline and Week 16
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 16
Change from baseline reflects the Week 16 value minus the Week 0 value.
Time frame: Baseline and Week 16
Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 16
Percent change from baseline was calculated as the Week 16 value minus the Week 0 value, divided by the Week 0 value ×100%.
Time frame: Baseline and Week 16
Percent Change From Baseline in Total Cholesterol (TC) at Week 16
Percent change from baseline was calculated as the Week 16 value minus the Week 0 value, divided by the Week 0 value ×100%.
Time frame: Baseline and Week 16
Percent Change From Baseline in Apolipoprotein B (Apo B) at Week 16
Percent change from baseline was calculated as the Week 16 value minus the Week 0 value, divided by the Week 0 value ×100%.
Time frame: Baseline and Week 16
Percent Change From Baseline in Non-high Density Lipoprotein Cholesterol (Non-HDL-C) at Week 16
Percent change from baseline was calculated as the Week 16 value minus the Week 0 value, divided by the Week 0 value ×100%.
Time frame: Baseline and Week 16
Percent Change From Baseline in Triglycerides (TG) at Week 16
Percent change from baseline was calculated as the Week 16 value minus the Week 0 value, divided by the Week 0 value ×100%.
Time frame: Baseline and Week 16
Percent Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C) at Week 16
Percent change from baseline was calculated as the Week 16 value minus the Week 0 value, divided by the Week 0 value ×100%.
Time frame: Baseline and Week 16
Percent Change From Baseline in Very Low-density Lipoprotein Cholesterol (VLDL-C) at Week 16
Percent change from baseline was calculated as the Week 16 value minus the Week 0 value, divided by the Week 0 value ×100%.
Time frame: Baseline and Week 16
Percentage of Participants With A1C Level <7% at Week 16
Percentage of participants achieving glycemic goal (A1C \<7%) after 16 weeks of treatment. Data as observed.
Time frame: Week 16
| Milestone | Sitagliptin/Simvastatin FDC | Sitagliptin | Simvastatin |
|---|---|---|---|
| Started | 100 | 99 | 100 |
| Treated with double-blind study drug | 100 | 97 | 98 |
| Completed | 38 | 36 | 43 |
| Not completed | 62 | 63 | 57 |
| Withdrew: Study terminated by sponsor | 45 | 43 | 43 |
| Withdrew: Withdrawal by subject | 2 | 5 | 2 |
| Withdrew: Protocol specified criteria | 2 | 3 | 1 |
| Withdrew: Adverse event | 2 | 2 | 2 |
| Withdrew: Lost to follow-up | 7 | 2 | 2 |
| Withdrew: Non-compliance with study drug | 0 | 1 | 0 |
| Withdrew: Physician decision | 0 | 0 | 1 |
| Withdrew: Protocol violation | 4 | 5 | 4 |
| Withdrew: Not treated with double-blind study drug | 0 | 2 | 2 |
A1C is measured as percent. Thus, this change from baseline reflects the Week 16 A1C percent minus the Week 0 A1C percent. This primary outcome measure only includes results for sitagliptin/simvastatin FDC vs. sitagliptin. Results for simvastatin are presented below under secondary outcome measures.
| Percent | Sitagliptin/Simvastatin FDC | Sitagliptin |
|---|---|---|
| Change From Baseline in Hemoglobin A1C (A1C) at Week 16 (Sitagliptin/Simvastatin FDC vs. Sitagliptin) | -0.41 (-0.64 to -0.17) | -0.59 (-0.83 to -0.36) |
Excludes data after rescue therapy. Adverse event is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the Sponsor's product, whether or not considered related to the use of the product.
| Participants | Sitagliptin/Simvastatin FDC | Sitagliptin | Simvastatin |
|---|---|---|---|
| Number of Participants Who Experienced at Least One Adverse Event (AE) | 13 | 13 | 17 |
Excludes data after rescue therapy. Adverse event is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the Sponsor's product, whether or not considered related to the use of the product.
| Participants | Sitagliptin/Simvastatin FDC | Sitagliptin | Simvastatin |
|---|---|---|---|
| Number of Participants Who Discontinued Study Drug Due to an Adverse Event | 2 | 1 | 2 |
A1C is measured as percent. Thus, this change from baseline reflects the Week 16 A1C percent minus the Week 0 A1C percent. This primary outcome measure only includes results for sitagliptin/simvastatin FDC vs. simvastatin. Results for sitagliptin are presented above under primary outcome measures.
| Percent | Sitagliptin/Simvastatin FDC | Simvastatin |
|---|---|---|
| Change From Baseline in A1C at Week 16 (Sitagliptin/Simvastatin FDC vs. Simvastatin) | -0.41 (-0.64 to -0.17) | 0.21 (-0.02 to 0.45) |
Change from baseline reflects the Week 16 value minus the Week 0 value.
| mg/dL | Sitagliptin/Simvastatin FDC | Sitagliptin | Simvastatin |
|---|---|---|---|
| Change From Baseline in Fasting Plasma Glucose (FPG) at Week 16 | -7.9 (-21.0 to 5.2) | -9.6 (-23.4 to 4.1) | 21.3 (7.9 to 34.7) |
Percent change from baseline was calculated as the Week 16 value minus the Week 0 value, divided by the Week 0 value ×100%.
| Percent change | Sitagliptin/Simvastatin FDC | Sitagliptin | Simvastatin |
|---|---|---|---|
| Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 16 | -21.6 (-32.3 to -10.8) | 4.0 (-6.9 to 14.9) | -26.9 (-37.5 to -16.3) |
Percent change from baseline was calculated as the Week 16 value minus the Week 0 value, divided by the Week 0 value ×100%.
| Percent change | Sitagliptin/Simvastatin FDC | Sitagliptin | Simvastatin |
|---|---|---|---|
| Percent Change From Baseline in Total Cholesterol (TC) at Week 16 | -18.4 (-26.6 to -10.2) | -0.4 (-8.6 to 7.9) | -18.4 (-26.4 to -10.4) |
Percent change from baseline was calculated as the Week 16 value minus the Week 0 value, divided by the Week 0 value ×100%.
| Percent change | Sitagliptin/Simvastatin FDC | Sitagliptin | Simvastatin |
|---|---|---|---|
| Percent Change From Baseline in Apolipoprotein B (Apo B) at Week 16 | -16.9 (-27.0 to -6.8) | 3.3 (-7.1 to 13.7) | -19.8 (-30.0 to -9.6) |
Percent change from baseline was calculated as the Week 16 value minus the Week 0 value, divided by the Week 0 value ×100%.
| Percent change | Sitagliptin/Simvastatin FDC | Sitagliptin | Simvastatin |
|---|---|---|---|
| Percent Change From Baseline in Non-high Density Lipoprotein Cholesterol (Non-HDL-C) at Week 16 | -23.9 (-33.9 to -13.9) | 0.6 (-9.5 to 10.7) | -24.2 (-34.0 to -14.4) |
Percent change from baseline was calculated as the Week 16 value minus the Week 0 value, divided by the Week 0 value ×100%.
| Percent change | Sitagliptin/Simvastatin FDC | Sitagliptin | Simvastatin |
|---|---|---|---|
| Percent Change From Baseline in Triglycerides (TG) at Week 16 | -20.4 (-51.9 to 11.1) | -4.9 (-39.5 to 29.7) | -10.1 (-52.1 to 31.9) |
Percent change from baseline was calculated as the Week 16 value minus the Week 0 value, divided by the Week 0 value ×100%.
| Percent change | Sitagliptin/Simvastatin FDC | Sitagliptin | Simvastatin |
|---|---|---|---|
| Percent Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C) at Week 16 | 2.5 (-2.7 to 7.8) | 2.0 (-3.3 to 7.4) | 2.1 (-3.0 to 7.3) |
Percent change from baseline was calculated as the Week 16 value minus the Week 0 value, divided by the Week 0 value ×100%.
| Percent change | Sitagliptin/Simvastatin FDC | Sitagliptin | Simvastatin |
|---|---|---|---|
| Percent Change From Baseline in Very Low-density Lipoprotein Cholesterol (VLDL-C) at Week 16 | -17.5 (-33.8 to -1.2) | 12.9 (-4.2 to 29.9) | -2.2 (-18.9 to 14.5) |
Percentage of participants achieving glycemic goal (A1C \<7%) after 16 weeks of treatment. Data as observed.
| Percentage of participants | Sitagliptin/Simvastatin FDC | Sitagliptin | Simvastatin |
|---|---|---|---|
| Percentage of Participants With A1C Level <7% at Week 16 | 29.9 | 29.6 | 17.6 |
Collected over Up to 18 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sitagliptin/Simvastatin FDC | — | 1/100 (1%) | 0/100 (0%) |
| Sitagliptin | — | 0/97 (0%) | 0/97 (0%) |
| Simvastatin | — | 1/98 (1%) | 0/98 (0%) |
| Event | Sitagliptin/Simvastatin FDC | Sitagliptin | Simvastatin |
|---|---|---|---|
| Musculoskeletal chest painMusculoskeletal and connective tissue disorders | 0/100 | 0/97 | 1/98 |
| Abdominal painGastrointestinal disorders | 1/100 | 0/97 | 0/98 |
| Intestinal obstructionGastrointestinal disorders | 1/100 | 0/97 | 0/98 |
All participants randomized population. Study specific baseline characteristics include all randomized participants with data.
| Age, Continuous(Years) | Sitagliptin/Simvastatin FDC | Sitagliptin | Simvastatin | Total |
|---|---|---|---|---|
| Mean | 54.9 ± 10.2 | 54.2 ± 10.3 | 54.9 ± 10.0 | 54.7 ± 10.1 |
| Sex: Female, Male(Participants) | Sitagliptin/Simvastatin FDC | Sitagliptin | Simvastatin | Total |
|---|---|---|---|---|
| Female | 45 | 52 | 49 | 146 |
| Male | 55 | 47 | 51 | 153 |
| Hemoglobin A1c (A1C)(Percent) | Sitagliptin/Simvastatin FDC | Sitagliptin | Simvastatin | Total |
|---|---|---|---|---|
| Mean | 8.16 ± 0.94 | 8.15 ± 1.09 | 8.22 ± 1.19 | 8.18 ± 1.08 |
| Fasting plasma glucose (FPG)(mg/dL) | Sitagliptin/Simvastatin FDC | Sitagliptin | Simvastatin | Total |
|---|---|---|---|---|
| Mean | 169.9 ± 42.3 | 175.9 ± 48.6 | 175.7 ± 49.3 | 173.8 ± 46.8 |
| Low-density lipoprotein cholesterol (LDL-C)(mg/dL) | Sitagliptin/Simvastatin FDC | Sitagliptin | Simvastatin | Total |
|---|---|---|---|---|
| Mean | 106.5 ± 26.7 | 103.9 ± 24.2 | 100.9 ± 22.0 | 103.7 ± 24.4 |
| Total cholesterol (TC)(mg/dL) | Sitagliptin/Simvastatin FDC | Sitagliptin | Simvastatin | Total |
|---|---|---|---|---|
| Mean | 189.3 ± 30.9 | 187.7 ± 29.6 | 183.5 ± 28.4 | 186.8 ± 29.6 |
| Apolipoprotein B (Apo B)(mg/dL) | Sitagliptin/Simvastatin FDC | Sitagliptin | Simvastatin | Total |
|---|---|---|---|---|
| Mean | 97.8 ± 19.0 | 95.4 ± 19.0 | 94.1 ± 17.2 | 95.8 ± 18.4 |
| Non high-density lipoprotein cholesterol (non-HDL-C)(mg/dL) | Sitagliptin/Simvastatin FDC | Sitagliptin | Simvastatin | Total |
|---|---|---|---|---|
| Mean | 141.7 ± 30.9 | 139.5 ± 29.9 | 136.5 ± 27.1 | 139.2 ± 29.3 |
3 further baseline measures are reported on the registry.
No study locations are listed for this record.
Plan to share: Yes — https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
No publications or documents are linked to this record.
Ran from Oct 2012 to primary completion in Nov 2013, 12 months.
Results were first posted in Oct 2014, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Sitagliptin · Simvastatin